According to the World Health Organization ‘Antibiotic resistance is becoming a public health emergency of yet unknown proportions’. In the European Union, antimicrobial resistance, or AMR is responsible for some 25.000 deaths every year. Meanwhile, new forms of resistance continue to arise and spread, leaving clinicians with few weapons to bring infections under control. Yet despite the recognised need for new antibiotics, the reality is that only two new classes of antibiotics have been brought to the market in the last three decades.

COMBACTE is one of the projects of the IMI’s New Drugs 4 Bad Bugs (ND4BB) programme which tackles the scientific, regulatory, and economic challenges of developing new antibiotics to combat antibiotic resistance in Europe.

This research project receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115523, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.

Produced by Fast Facts
Commissioned by COMBACTE
Thanks to Ron de Winter, Claudia Maissan, Sonja El Yandouzi, Arief Lalmohamed, Anneke Nijsse and other contributors at the Utrecht University Medical Centre; Elodie Pfender, University of Limoges; Américo Agostinho, Killian Joëlle and other contributors at the Geneva University Hospital.

With images from: Utrecht University Medical Centre

Made by: Moira van Dijk and Jasmijn Snoijink 2014
In cooperation with
Camera & editing: Wouter Boes
Music: Daan van West
Voice-over: Claire-Marie Martis – Media-Darling
Graphic design: SproetS

combacte.com
imi.europa.eu

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…